Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
25
APLT Quote, Financials, Valuation and Earnings
Last price:
$0.37
Seasonality move
:
-2.29%
Day range:
$0.37 - $0.40
52-week range:
$0.30 - $10.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.44x
Volume:
1.9M
Avg. volume:
2.3M
1-year change:
-92.67%
Market cap:
$52.6M
Revenue:
$455K
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingApplied Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.63, Applied Therapeutics has an estimated upside of 1412.91% from its current price of $0.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.37.
Fair Value
-
According to the consensus of 4 analysts, Applied Therapeutics has 1412.91% upside to fair value with a price target of $5.63 per share.
APLT vs. S&P 500
-
Over the past 5 trading days, Applied Therapeutics has underperformed the S&P 500 by -1.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Applied Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Applied Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Applied Therapeutics reported revenues of $122K.
Earnings Growth
-
Applied Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Applied Therapeutics reported earnings per share of -$0.15.
Enterprise value:
1.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-192.86%
Net Income Margin (TTM):
--
Return On Equity:
-797.82%
Return On Invested Capital:
-790.52%
Operating Margin:
-24379.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $190K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$70.7M | -$74.8M | -$108.7M | -$21.1M | -$25.5M | |
| EBITDA | -$70.3M | -$74.4M | -$108.3M | -$21M | -$25.4M | |
| Diluted EPS | -$1.70 | -$1.84 | -$0.43 | -$0.67 | -$0.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $154.4M | $63.6M | $29.1M | $150.9M | $54M | |
| Total Assets | $156.2M | $65M | $30M | $151.2M | $56.9M | |
| Current Liabilities | $19.8M | $22.2M | $33.3M | $83.9M | $18M | |
| Total Liabilities | $21M | $23M | $34.1M | $83.9M | $20.2M | |
| Total Equity | $135.2M | $42M | -$4.1M | $67.3M | $36.7M | |
| Total Debt | -- | -- | $534K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.7M | -$67.1M | -$94M | -$18.9M | -$28.6M | |
| Cash From Investing | $17.5M | -- | -- | -- | -- | |
| Cash From Financing | $27.9M | $190.7M | -$1.7M | $115.5M | -- | |
| Free Cash Flow | -$60.7M | -$67.1M | -$94M | -$18.9M | -$28.6M | |
APLT
Sector
Market Cap
$52.6M
$33.4M
Price % of 52-Week High
3.5%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
-13.59%
-0.6%
1-Year Price Total Return
-92.67%
-36.6%
Beta (5-Year)
1.858
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.37
200-day SMA
Sell
Level
$3.16
Bollinger Bands (100)
Sell
Level
0.38 - 0.58
Chaikin Money Flow
Sell
Level
-128.6M
20-day SMA
Sell
Level
$0.41
Relative Strength Index (RSI14)
Sell
Level
45.44
ADX Line
Buy
Level
17.52
Williams %R
Neutral
Level
-65.1042
50-day SMA
Sell
Level
$0.40
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-90.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.0833)
Sell
CA Score
(Annual)
Level (-8.1105)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.8961)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Stock Forecast FAQ
In the current month, APLT has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The APLT average analyst price target in the past 3 months is $5.63.
-
Where Will Applied Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Applied Therapeutics share price will rise to $5.63 per share over the next 12 months.
-
What Do Analysts Say About Applied Therapeutics?
Analysts are divided on their view about Applied Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Applied Therapeutics is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Applied Therapeutics's Price Target?
The price target for Applied Therapeutics over the next 1-year time period is forecast to be $5.63 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is APLT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Applied Therapeutics is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of APLT?
You can purchase shares of Applied Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Applied Therapeutics shares.
-
What Is The Applied Therapeutics Share Price Today?
Applied Therapeutics was last trading at $0.37 per share. This represents the most recent stock quote for Applied Therapeutics. Yesterday, Applied Therapeutics closed at $0.37 per share.
-
How To Buy Applied Therapeutics Stock Online?
In order to purchase Applied Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is down 5.6% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is down 2.96% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.69% over the past day.
